COMPANY

Nuravax, Inc.

HQ: Irvine, CA source · nuravax.com ↗ · West Coast

Also known as Nuravax · 4 sources

Keywords: neurology vaccine Alzheimer Disease Preclinical Alzheimer's Disease Alzheimers Disease Prevention AV-1959R (Abeta vaccine)

Location: Irvine, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.26M (SBIR Phase II 4R44AG091903-02, extension, notice Jul 21, 2026). NIH RePORTER 4R44AG091903-02 (Jul 21, 2026)
Evidence (1 event)
- Jul 21, 2026 · NIH RePORTER 4R44AG091903-02
  Organization: NURAVAX, INC.; City/State: IRVINE, CA; Project number: 4R44AG091903-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 1257282; Administering IC: National Institute on Aging; Project title: Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 25, 2026 Trial start 1: DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau source ↗
Jun 12, 2024 Trial start I: Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine source ↗

Apr 1, 2027 (ESTIMATED) · 1 · DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau · NCT07142278

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07142278	DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau	1	Recruiting	Sep 25, 2026	Apr 1, 2027 (estimated)
NCT06831812	Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine	I	Completed	Jun 12, 2024	Dec 1, 2025 (actual)

Annual award amounts. Total $1.8M.

Jul 21, 2026 NIH award 4R44AG091903-02 FY2026: $1,257,282 awarded for that fiscal year; activity R44 (SBIR); PI CRIBBS, DAVID HASTINGS; recipient as written: NURAVAX, INC., IRVINE, CA. Evaluate the Safety, Tolerability, and Immun source ↗
Mar 25, 2025 NIH award 1R44AG091903-01 FY2025: $499,754 awarded for that fiscal year; activity R44 (SBIR); PI CRIBBS, DAVID HASTINGS; recipient as written: NURAVAX, INC., IRVINE, CA. Evaluate the Safety, Tolerability, and Immunog source ↗